Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nvidia's revenue forecast lifts Wall Street; investors eye the Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c
August 14, 2024 4:20 PM EDTArcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($0.42), $0.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $29.09 million.
For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.
... More